| 0 (0%) | 09-27 14:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.16 |
1-year : | 2.52 |
| Resists | First : | 1.85 |
Second : | 2.16 |
| Pivot price | 1.6 |
|||
| Supports | First : | 1.46 |
Second : | 1.22 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.53 |
| MA(100) : | 1.71  |
MA(250) : | 4.03 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 91.2 |
D(3) : | 87.7 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 9.05 | Low : | 1.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed above the upper band by 2.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.87 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.82 - 1.84 | 1.84 - 1.86 |
Fri, 19 Sep 2025
RedHill Biopharma Granted Nasdaq Compliance Extension - MSN
Mon, 15 Sep 2025
RedHill Biopharma Reports Strong First Half 2025 Results and Strategic Advances - MSN
Fri, 05 Sep 2025
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - PR Newswire
Mon, 18 Aug 2025
90% H. Pylori Eradication: RedHill's Talicia Hits First Global Sales Milestone with Patent Until 2042 - Stock Titan
Mon, 21 Jul 2025
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 3 (M) |
| Shares Float | 16,650 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 77 (K) |
| Shares Short P.Month | 107 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.46 |
| Profit Margin | -97.6 % |
| Operating Margin | -107.4 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 58.5 % |
| Gross Profit (p.s.) | 1.84 |
| Sales Per Share | 2.86 |
| EBITDA (p.s.) | -2.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.76 |
| Price to Sales | 0.64 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|